Target Price | $21.25 |
Price | $7.61 |
Potential |
179.24%
register free of charge
|
Number of Estimates | 8 |
8 Analysts have issued a price target Altimmune, Inc. 2025 .
The average Altimmune, Inc. target price is $21.25.
This is
179.24%
register free of charge
$28.00
267.94%
register free of charge
$10.00
31.41%
register free of charge
|
|
A rating was issued by 9 analysts: 7 Analysts recommend Altimmune, Inc. to buy, 2 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Altimmune, Inc. stock has an average upside potential 2025 of
179.24%
register free of charge
|
Dec '23 |
2024 Estimates |
|
---|---|---|
Revenue Million $ | 0.43 | 0.00 |
714.29% | 99.12% | |
EBITDA Margin | -19,309.30% | -2,735,350.40% |
115.51% | 14,065.97% | |
Net Margin | -27,455.63% | -2,513,048.91% |
114.93% | 9,053.13% |
8 Analysts have issued a sales forecast Altimmune, Inc. 2024 . The average Altimmune, Inc. sales estimate is
This results in the following potential growth metrics:
3 Analysts have issued an Altimmune, Inc. EBITDA forecast 2024. The average Altimmune, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
3 Altimmune, Inc. Analysts have issued a net profit forecast 2024. The average Altimmune, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '23 |
2024 Estimates |
|
---|---|---|
Earnings Per Share $ | -1.66 | -1.33 |
8.29% | 19.88% | |
P/E | negative | |
EV/Sales | 107,629.33 |
3 Analysts have issued a Altimmune, Inc. forecast for earnings per share. The average Altimmune, Inc. <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2024, the Altimmune, Inc. stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
Altimmune, Inc....
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.